Associations between expression of indoleamine 2, 3-dioxygenase enzyme and inflammatory cytokines in patients with first-episode drug-naive Schizophrenia

Yan Zhang1,2,3, Han Shi1,2,3, Ge Yang1,2,3, Yongfeng Yang1,2,3, Wenqiang Li1,2,3, Meng Song1,2,3, Minglong Shao1,2,3, Xi Su1,2,3✉ and Luxian Lv1,2,3

© The Author(s) 2021

The indoleamine 2,3-dioxygenase (IDO) enzyme is the first rate-limiting enzyme of the tryptophan degradation pathway in which dysfunction of neuroactive metabolites has been implicated in the pathophysiology of schizophrenia. Inflammatory molecules such as pro-inflammatory cytokines could enhance the activity of IDO. There are few studies on the expression of IDO levels and its correlation with levels of inflammatory cytokines in first-episode drug-naive patients with schizophrenia. One hundred inpatients (female = 33, male = 67) with first-episode drug-naive schizophrenia entered a 6-week, double-blind, randomized, placebo-controlled clinical trial. All individuals were assigned celecoxib or placebo combined with risperidone. Serum levels of IDO and six inflammatory cytokines (IL-1β, IL-6, TNF-α IL-17, IL-4, and INF-γ) were measured. The Positive and Negative Syndrome Scale (PANSS) was used to assess the severity of psychotic symptoms. Compared to healthy subjects, patients had significantly elevated levels of IDO and six cytokines at baseline. Over the 6-week treatment period, the decrease in the levels of IDO and TNF-α and the improvement in the PANSS total score, positive scores, and negative scores in the celecoxib group were significantly greater than in the placebo group. There was a significantly positive correlation between IDO levels and the PANSS negative scores and between IDO levels and TNF-α and IFN-γ levels in the celecoxib group. These findings showed abnormal expression of IDO levels which correlated with negative symptoms and pro-inflammatory cytokine levels in patients with first-episode drug-naive schizophrenia, suggesting the important role of IDO in the pathological mechanism of schizophrenia. Registration number: ChiCTR2000041403.

Translational Psychiatry (2021)11:595; https://doi.org/10.1038/s41398-021-01688-x

INTRODUCTION

Schizophrenia is a common severe mental illness with a lifetime prevalence of about 1% worldwide [1]. Because of genetic mutations and environmental factors, the development of schizophrenia is a very complex process and is determined by multistage factors. Accumulating evidence suggests that immune dysfunction, caused by autoimmune reaction [2], viral infection [3], or macrophage-T-lymphocyte activation [4] plays an important role in the pathogenesis of schizophrenia.

The immune hypothesis presents a possible treatment for patients with schizophrenia. Pharmacological studies and animal experiments have found that some agents with anti-inflammatory properties, such as the anti-inflammatory drug minocycline, can improve psychotic symptoms [5–8]. The underlying mechanisms of immune dysregulation are associated with inflammation in the central nervous system (CNS), such as changes in the activity status of microglia cells [9]. Minocycline can cross the blood-brain barrier to suppress activated microglia cells, and ultimately improve the negative symptoms of schizophrenia [6, 10, 11]. Other studies have shown the potential anti-inflammatory properties of many psychotropic agents, such as antipsychotics, selective serotonin reuptake inhibitors, lithium, and valproate acid [3, 12].

Therefore, anti-inflammatory drugs are potential candidates as antipsychotic compounds. The cyclooxygenase-2 (COX-2) inhibitor celecoxib is a non-steroidal anti-inflammatory drug, COX-2 is an enzyme synthesizing PGE involved in inflammatory processes [13]. In vivo animal experiments have suggested that COX-2 inhibition can limit the increase in the production of the pro-inflammatory cytokines IL-1β and TNFα, as well that of PGE2 [14]. COX-2 inhibitors (mainly celecoxib) exhibited antipsychotic properties in vitro and in animal studies [15]. However, clinical trials of celecoxib as an adjunct to antipsychotics in the treatment of schizophrenia have been inconsistent [16–19]. These discordances may be related to a number of factors, such as sample size, disease state (acute versus chronic), and disease duration. Thus, compared to chronic or long-term medicated patients, drug-naive, first-episode schizophrenia patients are of unique value in exploring the neuropathological processes of the disease and in developing new drugs by minimizing potential confounders.

Tryptophan (Trp) is an essential amino acid and is necessary for cell survival and protein synthesis. The kynurenine pathway (KP) is quantitatively the most important, accounting for ~95% of Trp metabolism and involves several neuroactive metabolites. Indoleamine 2,3-dioxygenase (IDO) is the initial and rate-limiting
enzyme in the KP and catalyzes Trp into N-formyl-kynurenine which is a precursor of some neuroactive metabolites such as kynurenic acid (KYNA), an endogenous antagonist of the N-methyl-D-aspartate (NMDA) receptor and a7 nicotinic acetylcholine receptor (a7nAChR) [20], and the NMDA receptor agonist quinolinic acid. When there is inflammation, infection, or oxidative stress, pro-inflammatory molecules such as cytokines and reactive oxygen species can enhance the activity of the enzyme IDO. Inhibition of the inflammatory process may impede IDO-mediated Trp catabolism [21]. For example, the pro-inflammatory cytokine interferon (IFN-γ) can potently induce both the enzymatic activity and gene expression of IDO [22]. Other pro-inflammatory cytokines, such as prostaglandin (PGE) 2 or tumor necrosis factor-alpha (TNF-α), induce an increase in IDO activity by acting in a synergistic manner with IFN-γ [23]. However, anti-inflammatory cytokines such as interleukin (IL)-4 inhibit IDO activity [24]. So far, studies on the correlation between inflammatory cytokines and IDO in psychiatric disorders has mainly focused on depression. Although there is no direct evidence, previous studies have found that increased IDO activity, induced by pro-inflammatory cytokines, can lead to the development of depression [25–27]. There are few studies on the correlation between IDO and cytokines in schizophrenia, and further studies are needed.

A previous study found that the COX-2 inhibitor celecoxib inhibits IDO-mediated immune tolerance through regulatory T cells [28]. In another study, celecoxib reverses the IFN-α-induced increase in the kynurenine/Trp ratio, indicative of IDO activation [27]. However, it is unclear whether celecoxib is involved in the regulation of IDO activity in schizophrenia.

The present study is a 6-week, randomized, double-blind, and placebo-controlled trial to investigate the expression of IDO in serum blood of first-episode drug-naive schizophrenia patients and to explore the correlation between IDO and various inflammatory cytokines by using the COX2 inhibitor celecoxib. Based on previously reported results, we hypothesized that there would be abnormally elevated IDO expression in the peripheral blood of patients with first-episode schizophrenia, and IDO expression levels would be correlated with the pro-inflammatory cytokine levels and the severity of psychiatric symptoms.

METHODS
Design
This was a 6-week, randomized, double-blind, and placebo-controlled trial to investigate the expression of IDO in serum blood of first-episode drug-naive schizophrenia patients, and to explore the correlation between IDO and various inflammatory cytokines. The study protocol was approved by the Ethics Committee of The Second Affiliated Hospital of Xinxiang Medical University. Participant recruitment occurred from April 2019 to October 2020. All participants provided written informed consent. The trial is registered with ClinicalTrials.gov (ChiCTR2000041403).

Subjects
A total of 113 inpatients with schizophrenia were recruited from the Department of Psychiatry of The Second Affiliated Hospital of Xinxiang Medical University. The inclusion criteria were: (1) aged 16–55 years; (2) meeting the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text Revision (DSM-IV-TR) criteria for schizophrenia; (3) score on the Positive and Negative Syndrome Scale (PANSS) > 60; (4) duration of disease less than 6 months; (5) antipsychotic-naive or treatment duration < 2 weeks before study entry; (6) an intelligence quotient (IQ) of at least 70; (7) at least 6 years of formal education; and (8) Han Chinese ethnicity. Fifty healthy controls were recruited for this study from the local community through advertisements. Psychiatric conditions were ruled out in healthy controls using the Structured Clinical Interview for DSM Disorders (SCID). In addition, a thorough physical exam was completed by the same research psychiatrists to rule out any medical conditions. The exclusion criteria for all participants included: (1) a psychiatric diagnosis other than schizophrenia (determined by SCID); (2) comorbid serious or unstable medical conditions, or significant inflammatory or immune conditions, including heart disease, epilepsy, hepatic or renal diseases, diabetes, aplastic anemia, systemic lupus erythematosus or asthma; (3) treatment with anti-inflammatory drugs (such as celecoxib, β-lactam antibiotics), hormones or immunosuppressant agents in the 6 months before study entry; (4) contraindication to celecoxib treatment; (5) planning to become pregnant, or were pregnant or breastfeeding.

Randomization and masking
After screening, all individuals with first-episode drug-naive schizophrenia entered a 6-week, double-blind, placebo-controlled study. All patients were randomized to celecoxib (200 mg/day) or placebo, as additional therapy to risperidone 4 mg to 6 mg/day, by a dynamic randomization method called minimization that equalizes the treatment groups across stratification variables such as gender and age. The random code was generated at the off-site hospital clinical drug trial base and sent to the off-site clinical trial pharmacy. To ensure concealment of the treatment assignment, randomization was conducted by a research pharmacist at a separate facility and medication was provided in coded containers of identical-appearing capsules of celecoxib or placebo, which were manufactured and dispensed by the same pharmaceutical manufacturer. To maintain blinding, all subjects took a capsule of 200 mg celecoxib or placebo every day depending on the randomization group. The dose of risperidone was gradually increased from 1 mg per day and adjusted from 4 mg to 6 mg/ day according to the patient’s condition in 2 weeks. According to the needs of the disease, trihexyphenidyl and propranolol could be used to relieve the side effects of drugs, and benzodiazepine could be used to improve sleep. All study personnel, including participants, treating team, statistician, investigators, and assessors were blinded to treatment assignment for the study duration.

Clinical measures
At baseline and 6 weeks of follow-up, PANSS scores were collected to record the treatment efficacy. Investigators completed training for these study scales and showed excellent inter-rater reliability and consistency on the scales (Kappa = 0.85).

Measurement of serum IDO and cytokine levels
Serum levels of IDO and cytokines (TNF-α, IL-1β, IFN-γ, IL-4, IL-6, IL-17) were determined at baseline and at 6 weeks of follow-up. Venous blood was collected from the forearm between 6 and 7 a.m. following an overnight fast. Serum levels of IDO and six cytokines were measured by quantitative enzyme-linked immunosorbent assay (ELISA) using a commercially available kit: IDO (SEB547Hu, sensitivity: minimum detectable measurement ≤ 0.118 ng/mL) (Cloud-Clone, Wuhan, China), IFN-γ (SEA049Hu, sensitivity: minimum detectable measurement ≤ 6.1 pg/mL) (Cloud-Clone, Wuhan, China), IL-4 (SEA077Hu, sensitivity: minimum detectable measurement ≤ 5.9 pg/mL) (Cloud-Clone, Wuhan, China), IL-6 (SEA079Hu, sensitivity: minimum detectable measurement ≤ 3.2 pg/mL) (Cloud-Clone, Wuhan, China), and IL-17 (SEA063Hu, sensitivity: 5.5 pg/mL) (Cloud-Clone, Wuhan, China), TNF-α (DTA00D, sensitivity: 6.23 pg/mL) (R&D Systems, USA), IL-1β (DLB50, sensitivity: 1 pg/mL) (R&D Systems, USA). All ELISA kits used in this study have been cross-reactivity validation of existing related factors to ensure their specificity. All assays were blinded to group or behavior information until after the results were finalized.

Outcomes
The primary outcomes were circulating IDO levels at baseline and week 6. The secondary outcomes were serum levels of target cytokines and total score on the PANSS, all subscale scores on the PANSS at baseline and week 6.

Statistical analysis
Statistical analysis was conducted using the SPSS software (version 23.0; SPSS Inc., Chicago, IL, USA). Descriptive statistics were performed to summarize the demographic and clinical characteristics of the study sample. Group comparisons were performed using analysis of variance (ANOVA) and independent T-test for continuous variables and Chi-square test for categorical variables. A paired sample T-test was used for intra-group comparison. A one-sample Kolmogorov–Smirnov test was used to examine each variable for normality. All data were tested to conform to normal distribution. Pearson’s correlation was used for the correlation analysis. For all analyses, a P value < 0.05 (2-tailed) was deemed statistically significant.
RESULTS

One hundred inpatients with first-episode drug-naive schizophrenia were screened for the study. These individuals were randomized to trial medication (50 patients in each group). Ninety-three patients (93%) completed the 6-week trial: 46 on celecoxib, 47 on placebo (see Fig. 1). Four patients in the celecoxib group and three patients in the placebo group dropped out before the end of the study. The dropouts from the celecoxib group were aged 29, 31, and 43 years (one woman, two men), and they dropped out at days 7, 23, 17, and 15, respectively. The reasons for dropping out were acute stomachache, worsening of psychosis, severe akathisia, and withdrawal of consent. The dropouts from the placebo group were aged 29, 31, and 40 years (two women, two men), and they dropped out at days 7, 23, 17, and 15, respectively. The reasons for dropping out were lost follow-up, worsening of psychosis, and severe akathisia. There were no significant differences among the three groups in terms of age, gender, or years of education. There was no significant difference in scores on the PANSS and on all subscales between the two treatment groups (see Table 1).

The serum levels of IDO of the two treatment groups were significantly higher than that of the healthy group ($t = 93.165, P = 0.000$). There was no significant difference in the IDO levels between the two treatment groups ($P = 0.683$) (see Table 2). Over the 6-week treatment period, there was a significant difference in the decrease in serum levels of IDO in both treatment groups ($P < 0.05$). The decrease in serum levels of IDO in the celecoxib group was significantly greater than in the placebo group at 6 weeks ($t = -2.383, P = 0.019$) (see Table 2, Fig. 2).

There was a significant improvement in scores on the PANSS and on all subscales over the 6 weeks of treatment in both groups of patients (all $P < 0.001$). The improvement in the PANSS total score, positive scores and negative scores in the celecoxib group was significantly greater than for the placebo group at 6 weeks ($t = -3.618, P = 0.000$; $t = -3.622, P = 0.000$; $t = -3.255, P = 0.002$) (see Table 3). No significant difference was observed in the improvement of the PANSS general score at 6 weeks between the two groups.

In order to analyze the effect of celecoxib on psychotic symptoms, we conducted correlation analyses between serum levels of IDO and the scores on the PANSS and on all subscales at baseline, and between the change in serum levels of IDO and the change in scores on the PANSS and on all subscales over 6 weeks in the two treatment groups using Pearson’s correlation analysis. There was a significant correlation between serum IDO levels and the PANSS negative symptom scores in all schizophrenia patients ($r = 0.260, P = 0.000$) (see Fig. 3A). The reduction in the PANSS negative score showed a significant positive correlation with the decrease in serum levels of IDO in the celecoxib group ($r = 0.142, P = 0.010$) (see Fig. 3B).

The serum levels of TNF-α, IL-1β, IL-6, IL-17, IL-4, and IFN-γ in the two treatment groups were significantly higher than those of healthy volunteers at baseline (all $P < 0.05$), and there was no significant difference in the levels of inflammatory cytokines between the two treatment groups (see Table 4). Over the 6-week treatment period, there were significant differences in the decrease in serum levels of TNF-α, IFN-γ, and IL-17 in both groups (all $P < 0.05$). A significant decrease in serum IL-1β levels was observed in the celecoxib group at 6 weeks compared to baseline ($P < 0.05$). No significant difference was observed in the serum levels of IL-4 or IL-6 in the two treatment groups before and after treatment. The decrease in serum levels of TNF-α in the celecoxib group was significantly greater than in the placebo group at 6 weeks ($t = -13.989, P = 0.000$) (see Table 4).

In order to analyze the correlation between IDO and cytokines, we determined the association between IDO levels and cytokines levels at baseline, and also between the change in IDO levels and the change in cytokines levels before and after treatment. There was a significant positive correlation between serum IDO levels and serum TNF-α levels in all schizophrenia patients at baseline ($r = 0.057, P = 0.021$) (see Fig. 4A). The change in IDO levels

---

**Table 1.** Demographic characteristics and clinical characteristics and serum measures for different subgroups of patients and healthy groups.

| Variable                  | Schizophrenia group | Healthy group (n = 50) | F/Φ2     | P   |
|---------------------------|---------------------|-----------------------|----------|-----|
|                           | Celecoxib group (n = 46) | Placebo group (n = 47) |          |     |
| Age (years)               | 30.46 ± 8.59        | 27.85 ± 6.97          | 29.96 ± 6.01 | 1.176 | 0.184 |
| Gender                    |                     |                       |          |     |
| Male                      | 34 (73.9)           | 29 (61.7)             | 34 (68.0) | 1.590 | 0.452 |
| Female                    | 12                  | 18                    | 16       |      |
| Education (years)         | 11.65 ± 2.72        | 10.96 ± 2.43          | 11.90 ± 2.91 | 1.566 | 0.212 |
| PANSS total               | 90.17 ± 10.61       | 94.00 ± 10.06         | –        | –1.785 | 0.078 |
| PANSS positive            | 23.96 ± 5.11        | 24.26 ± 3.08          | –        | –0.342 | 0.773 |
| PANSS negative            | 23.09 ± 5.02        | 24.17 ± 4.14          | –        | –1.136 | 0.259 |
| PANSS general             | 43.13 ± 7.17        | 45.57 ± 6.92          | –        | –1.672 | 0.098 |

Between-group differences were performed using ANOVA; Between-group differences were performed using independent sample T-test; Chi-square analysis was used for categorical variables.
patients with schizophrenia. Previous studies have shown increased KYN/TRP in the plasma of patients with schizophrenia. The kynurenine to tryptophan (KYN/Trp) ratio (KYN/TRP) is a routinely used indicator of IDO activity. IDO is the initial and rate-limiting enzyme in the KP and can accelerate Trp metabolism and promote the generation of downstream neuroactive metabolites. The kynurenine to Trp ratio (KYN/TRP) is a routinely used indicator of IDO activity. Previous studies showed that abnormal activation of IDO occurs early in the disease and that the increase in IDO expression is related to the disease itself, not the drug treatment. Treatment with risperidone monotherapy or risperidone in combination with celecoxib both decreases IDO levels, indicating that both risperidone and celecoxib can be involved in the regulation of IDO expression. Several studies have shown increased KYN/TRP in the plasma of patients with schizophrenia. However, there have been no direct studies on IDO expression. In the present study, we found significantly increased IDO levels in first-episode drug-naive patients with schizophrenia compared to healthy controls, which is consistent with the results of previous studies. These findings suggest that abnormal activation of IDO occurs early in the disease and that the increase in IDO expression is related to the disease itself, not the drug treatment. Treatment with risperidone showed a significant positive correlation with the decrease in serum TNF-α and IFN-γ levels in the celecoxib group ($r = 0.175$, $P = 0.004$; $r = 0.087$, $P = 0.046$) (see Fig. 4B, C). No correlation was found between IDO and other cytokines.

**DISCUSSION**

To our knowledge, this is the first study to examine peripheral IDO levels in first-episode drug-naive patients with schizophrenia and to explore the correlation between inflammatory molecules and IDO following treatment with the COX2 inhibitor, celecoxib. We had three major findings: (1) The elevated levels of IDO and inflammatory cytokines including IL-1β, IL-6, TNF-α, IL-17, IL-4, and IFN-γ can be observed in the early stages of schizophrenia; (2) IDO levels were significantly positively correlated with TNF-α and IFN-γ levels; (3) IDO levels were significantly positively correlated with negative symptoms of schizophrenia. These findings clarify the important role of IDO in the pathological mechanism of schizophrenia.

IDO is the initial and rate-limiting enzyme in the KP and can catalyze Trp into kynurenine. An increase in IDO expression or activity can accelerate Trp metabolism and promote the generation of downstream neuroactive metabolites. The kynurenine to Trp ratio (KYN/TRP) is a routinely used indicator of IDO activity. Previous studies have shown increased KYN/TRP in the plasma of patients with schizophrenia [29–31]. However, there have been no direct studies on IDO expression. In the present study, we found significantly increased IDO levels in first-episode drug-naive patients with schizophrenia compared to healthy controls, which is consistent with the results of previous studies. These findings suggest that abnormal activation of IDO occurs early in the disease and that the increase in IDO expression is related to the disease itself, not the drug treatment. Treatment with risperidone and celecoxib can be involved in the regulation of IDO expression. Although the methods and objects are different, the results of these studies all indicate that IDO may be a key node for COX2 inhibitors to participate in Trp metabolism and regulate downstream neuroactive metabolites of the KP. At present, there are no relevant studies on risperidone’s involvement in the regulation of IDO activity or expression. However, a large number of literature supports the anti-inflammatory properties of risperidone [11, 33–35]. For example, Zhang et al. revealed that risperidone reduced peripheral TNF-α levels in patients with schizophrenia [11]. Based on previous findings that pro-inflammatory cytokines can directly or indirectly increase IDO activity or gene expression, we speculated that risperidone may participate in the regulation of IDO expression through inflammatory factors, and then affect the KP. These views need to be tested in animal experiments.

As expected, the celecoxib-combined therapy had a significant effect on the improvement in PANSS negative symptom scores, as well as PANSS total scores and positive scores in first-episode

**Table 2.** Treatment outcome of IDO for different subgroups of patients and healthy group.

| Variable | Schizophrenia group | Healthy group (n = 50) | F/T | P  | P1 | P2 | P3 |
|----------|---------------------|------------------------|-----|----|----|----|----|
|          | Celecoxib group (n = 46) | Placebo group (n = 47) |     |    |    |    |    |
| IDO (ng/ml) | 9.03 ± 2.81 | 8.81 ± 3.42 | 2.60 ± 1.29 | 93.165 | 0.000 | 0.000 | 0.000 | 0.683 |
| Baseline | 5.34 ± 2.11 | 6.29 ± 1.71 | – | – | – | – | – |

Within-group differences were examined using paired T-test; Between-group differences were performed using ANOVA; Between-group differences were performed using independent sample T-test. P1: For between celecoxib group and healthy group; P2: For between placebo group and healthy group; P3: For between celecoxib group and placebo group.

*P < 0.05, for the 6-week time point and baseline.

**Table 3.** Main clinical outcome measures for celecoxib and placebo groups.

| Variable | Celecoxib group (n = 46) | Placebo group (n = 47) | T  | P  |
|----------|-------------------------|------------------------|----|----|
| PANSS total | 90.17 ± 10.61 | 94.00 ± 10.06 | –1.785 | 0.078 |
| Baseline | 58.50 ± 12.35 | 67.57 ± 11.84 | –3.618 | 0.000 |
| PANSS positive | 23.96 ± 5.11 | 24.26 ± 3.08 | –0.340 | 0.735 |
| Baseline | 14.57 ± 6.01 | 18.13 ± 6.01 | –3.255 | 0.002 |
| PANSS general | 43.13 ± 7.16 | 45.57 ± 6.92 | –1.672 | 0.098 |
| Baseline | 28.17 ± 6.28 | 30.02 ± 5.71 | –1.484 | 0.141 |

Within-group differences were examined using paired T-test. Between-group differences were performed using independent sample T-test. **P < 0.05, for the 6-week time point and baseline.**

**Fig. 2** Treatment outcome of IDO for celecoxib and placebo groups. IDO: indoleamine 2, 3-dioxygenase enzyme; celecoxib group: schizophrenia patients were treated with celecoxib combination with risperidone; placebo group: schizophrenia patients were treated with placebo combination with risperidone.
drug-naive patients with schizophrenia. In a previous meta-analysis on augmentation with anti-inflammatory medications, we observed that some agents with anti-inflammatory properties, including aspirin, estrogens, minocycline, and N-acetylcysteine (NAC) showed efficacy for improvement of psychiatric symptoms [36]. However, the results of augmentation with celecoxib for schizophrenia treatment are heterogeneous. In a randomized, prospective, double-blind clinical trial, celecoxib demonstrated therapeutic efficacy when administered as an add-on treatment in patients with acute exacerbation of schizophrenia who were treated with risperidone [17]. Another clinical trial using celecoxib and amisulpride in patients with the first manifestation of schizophrenia also showed positive results [18]. In two trials on patients with continuously symptomatic schizophrenia, no advantage of celecoxib could be observed [17, 19]. Together with these data, we conclude that the effect of celecoxib depends on the duration of the disease, that is, the advantage of celecoxib is observed in patients with the first manifestation of schizophrenia or in patients with acute episodes.

**Fig. 3** Correlation coefficients between IDO levels and PANSS negative score. A There was a significant correlation between serum IDO levels and the PANSS negative symptom scores in all schizophrenia patients. B The reduction in the PANSS negative score showed a significant positive correlation with the decrease in serum levels of IDO in the celecoxib group. \( P < 0.05 \).

### Table 4. Treatment outcome of inflammatory cytokines for different subgroups of patients and healthy groups.

| Variable       | Schizophrenia group | Healthy group (n = 50) | F/T | P     | P1 | P2 | P3 |
|----------------|---------------------|------------------------|-----|-------|----|----|----|
| Celecoxib group (n = 46) | Placebo group (n = 47) |
| **TNF-α (pg/ml)** |                      |                        |     |       |    |    |    |
| baseline       | 62.47 ± 0.57         | 62.67 ± 0.75           | 2.11 ± 0.59 | 143133.552 | 0.000 | 0.000 | 0.153 |
| 6 week         | 11.32 ± 0.19**       | 21.15 ± 4.81***        | –   | –13.989 | 0.000 |
| **IL-1β (pg/ml)** |                      |                        |     |       |    |    |    |
| baseline       | 2.46 ± 0.55          | 2.28 ± 0.49            | NA  | 1.656 | 0.101 |
| 6 week         | 1.93 ± 0.33**        | 2.01 ± 0.34            | –   | –1.147 | 0.254 |
| **INF-γ (pg/ml)** |                      |                        |     |       |    |    |    |
| baseline       | 448.79 ± 93.66       | 445.53 ± 85.20         | 5.60 ± 2.97 | 622.903 | 0.000 | 0.000 | 0.055 |
| 6 week         | 278.81 ± 112.88**    | 275.55 ± 103.28*       | –   | 0.352 | 0.726 |
| **IL-4 (pg/ml)** |                      |                        |     |       |    |    |    |
| baseline       | 22.77 ± 4.77         | 22.82 ± 5.74           | 0.016 ± 0.01 | 465.268 | 0.000 | 0.000 | 0.952 |
| 6 week         | 21.45 ± 4.42         | 21.26 ± 5.92           | –   | 0.179 | 0.858 |
| **IL-6 (pg/ml)** |                      |                        |     |       |    |    |    |
| baseline       | 15.01 ± 4.72         | 15.66 ± 7.29           | 0.385 ± 0.19 | 147.665 | 0.000 | 0.000 | 0.526 |
| 6 week         | 14.53 ± 6.09         | 14.76 ± 5.46           | –   | –1.192 | 0.848 |
| **IL-17 (pg/ml)** |                      |                        |     |       |    |    |    |
| baseline       | 19.46 ± 6.13         | 19.05 ± 6.26           | NA  | 0.319 | 0.751 |
| 6 week         | 12.22 ± 5.82**       | 13.30 ± 5.58*          | –   | –0.913 | 0.364 |

Between-group differences were performed using ANOVA; Between-group differences were performed using independent sample T-test. Within-group differences were examined using paired T-test. P1: For between celecoxib group and healthy group; P2: For between placebo group and healthy group; P3: For between celecoxib group and placebo group.

*P < 0.05, **P < 0.01, for between the 6-week time point and baseline.
In the present study, a significant positive correlation between IDO levels and the severity of negative symptoms was observed. Negative symptoms in schizophrenia, which can seriously impair functional ability, are often treated insufficiently by currently available antipsychotics. One of the possible mechanisms of negative symptoms is disruption of glutamatergic systems [11]. In a meta-analysis (n = 343) of 18 randomized placebo-controlled studies with glutamatergic drugs, Tuominen and colleagues found a mean reduction of four points on the PANSS-negative symptoms subscale [37]. Since one of the final neuroactive products of Trp metabolism is KYNA, which is the only endogenous NMDA receptor antagonist, we hypothesized that the mechanism by which IDO associates with negative symptoms is through the abnormal function of Trp metabolic pathways. Based on these findings, we are optimistic that agents regulating IDO such as celecoxib may be a new approach for the treatment of negative symptoms of schizophrenia.

Accumulating evidence suggests that dysregulations in components of the immune system are fundamentally linked to schizophrenia [38, 39]. Our findings of dysfunction of inflammatory cytokine levels in schizophrenia agreed with the previously mentioned cytokine-mediated immune disorders and demonstrated the anti-inflammatory properties of risperidone and celecoxib. A meta-analysis of 40 studies assessing cytokine alterations in acutely relapsed inpatients and those with first-episode psychosis found that some cytokines (IL-1β, IL-6, and transforming growth factor-beta (TGF-β)) may be state markers for acute exacerbations, while others (IL-12, IFN-γ, TNF-α, and sIL-2R) may be trait markers [40]. However, we observed inconsistent results in that there were significant decreases in serum levels of TNF-α, IL-1β, IFN-γ, and IL-17 after 6 weeks of treatment in first-episode drug-naïve patients with schizophrenia, while there was no change in levels of IL-4 and IL-6. In a 6-month follow-up study of first-episode drug-naïve schizophrenia, Song et al. found that serum IL-1β, IL-6, and TNF-α levels changed dynamically throughout the follow-up period [41]. These heterogeneous results may be attributed to differences in observed time points.

Given the evidence that the activity of IDO is strongly regulated by the immune system and more specifically by pro-inflammatory cytokines, such as IFN-γ, IL-6, IL-1β, and TNF-α [42, 43], we predict that in our study, changes in pro-inflammatory cytokines levels described above would affect IDO expression. A recent study found a significant correlation between IFN-γ and kynurenine, and a trend-level correlation between TNF-α and kynurenine levels in plasma from patients with schizophrenia, but no significant correlation between IL-6 and kynurenine [44]. Another study in patients with schizophrenia reported a positive correlation between plasma IL-1β and kynurenine levels [45]. In this study of patients with first-episode schizophrenia and relatively well-matched controls, significant positive correlations between IDO levels and TNF-α and INF-γ levels were observed. These results supported the idea that pro-inflammatory cytokines including TNF-α and INF-γ have a positive regulatory effect on IDO.

In addition, anti-inflammatory cytokines can play a role in the treatment of schizophrenia by regulating the expression and activity of IDO through inflammatory mechanisms. The advantage of this study is the vertical observation of changes in peripheral blood IDO expression in patients with first-onset drug-naïve schizophrenia, and the analysis of its association with peripheral blood cytokines and psychiatric symptoms. Compared with other previous studies, we studied the expression of IDO directly, instead of reflecting IDO activity via levels of downstream KP metabolites, such as kynurenine. Kynurenine itself is affected by many factors including smoking [46] and aerobic exercise [47]. However, there are also a few limitations. First, we only determined IDO expression in peripheral blood and did not determine the activity of IDO. Whether the change in expression levels can represent a change in an activity needs further verification. Second, with the exception of the IDO, we also need to determine the levels of other enzymes and neuroactive metabolites in the KP to fully understand the effects of pro-inflammatory and anti-inflammatory drugs on the KP. Third, we need to further examine the expression of IDO in the CNS. Although no studies have so far been able to confirm the consistency of central and peripheral IDO expression levels in patients with schizophrenia, our unpublished results of animal models of schizophrenia support the consistent trend of IDO changes in the two environments.

Despite these limitations, this study is the first to investigate the expression of IDO in peripheral blood of first-episode drug-naïve patients with schizophrenia, and to determine the correlation between inflammation and IDO. Our results show that there is abnormally elevated IDO expression in patients with first-episode drug-naïve schizophrenia, and IDO expression correlates with negative symptoms of schizophrenia and the levels of various pro-inflammatory cytokines in peripheral blood. These findings indicate the importance of IDO in the pathogenesis of schizophrenia.

REFERENCES
1. Phillips MR, Zhang J, Shi Q, Song Z, Ding Z, Pang S, et al. Prevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001–05: an epidemiological survey. Lancet. 2009;373:2041–53.
2. Strous RD, Shoenfeld Y. Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. J Autoimmun. 2006;27:71–80.
3. Benros ME, Mortensen PB, Eaton WW. Autoimmune diseases and infections as risk factors for schizophrenia. Ann N Y Acad Sci. 2012;1262:56–66.
4. Muller N, Riedel M, Gruber R, Achenhel M, Schwarz MJ. The immune system and schizophrenia. An integrative view. Ann N Y Acad Sci. 2000;917:456–67.
5. Chaves C, Marque CR, Maia-de-Oliveira JP, Wichert-Ana L, Ferrari TB, Santos AC, et al. Effects of minocycline add-on treatment on brain morphometry and cerebral perfusion in recent-onset schizophrenia. Schizophr Res. 2015;161:e39–45.
6. Seligren CM, Gracias J, Watmuff B, Biag JD, Thanos JM, Whitcombe PB, et al. Increased synaptic elimination by microglia in schizophrenia patient-derived models of synaptic pruning. Nat Neurosci. 2019;22:374–85.
7. Deakin B, Suckling J, Barnes T, Byrne K, Chaudhry IB, Dazzan P, et al. The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial. Lancet Psychiatry. 2018;5:885–94.
8. Keiser B, Gershon K, Eisenstein K, Petcu C, Ladea M, Sima D, et al. A randomized controlled trial of allopurinol vs placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder. Schizophr Res. 2012;138:35–38.
9. Fineberg AM, Ellman LM. Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia. Biol Psychiatry. 2013;73:951–66.
10. Zhang L, Zhao J. Profile of minocycline and its potential in the treatment of schizophrenia. Neuropsychiatr Dis Treat. 2014;10:1103–11.
11. Zhang L, Zheng H, Wu R, Zhu F, Kosten TR, Zhang XY, et al. Treatment with interferon-alpha (IFN alpha) of hepatitis C patients induces increased cytokine levels and plasma kynurenine in humans. J Interferon Cytokine Res. 2005;25:20–30.
12. Musso T, Guella GL, Brooks A, Longo DL, Varesio L. Interleukin-4 inhibits 2,3-dioxigenase expression in human monocytes. Blood. 1994;83:1408–11.
13. Maes M, Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, et al. Treatment with interferon-alpha (IFN alpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN-alpha induced depressive and anxiety symptoms and immune activation. Mol Psychiatry. 2001;6:475–85.
14. Capuron L, Neurauter G, Musselman DL, Lawson DH, Nemeroff CB, Fuchs D, et al. Interferon-alpha-induced changes in tryptophan metabolism: relationship to depression and paroxetine treatment. Biol Psychiatry. 2003;54:906–14.
15. Fischer CW, Eskelund A, Budac DP, Tillmann S, Liebenberg N, Ellingboe B, et al. Interferon-alpha treatment induces depression-like behaviour accompanied by elevated hippocampal quinolinic acid levels in rats. Behav Brain Res. 2015;293:166–72.
16. Lee SY, Choi HK, Lee KJ, Jung YJ, Hur GY, Jung KH, et al. The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulation T cells. J Immunother. 2009;32:22–28.
17. Barry S, Clarke G, Scully P, Dinan TG. Kynurenine pathway in psychosis: evidence of increased reactivity and upregulation. J Psychopharmacol. 2009;23:287–94.
18. Chiappelli J, Postolache TT, Kucurhon P, Rowland LM, Wijtenburg SA, Shukla DK, et al. Tryptophan Metabolism and White Matter Integrity in Schizophrenia. Neuropsychopharmacology. 2016;41:2587–95.
19. Schwieler L, Larsson MK, Skogh E, Kegel ME, Orhan F, Abdelmoaty S, et al. Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia-significance for activation of the kynurenic pathway. J Psychiatry Neurosci. 2015;40:126–33.
20. Schwieler L, Erhardt S, Erhardt C, Engelb P. Prostaglandin-mediated control of rat brain kynurenine acid synthesis–opposite actions by COX-1 and COX-2 isoforms. J Neural Transm. 2005;112:863–72.
21. Song X, Fan X, Li X, Zhang W, Gao J, Zhao J, et al. Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naive, first-episode schizophrenia. Psychopharmacology. 2014;231:319–25.
22. Chen S-L, Lee SY, Chang YH, Chen SH, Chu CH, Tzeng NS, et al. Inflammation in patients with schizophrenia: the therapeutic benefits of risperidone plus add-on dextromethorphan. J Neurommune Pharmacol. 2012;7:656–64.
23. Leonard BE, Schwartz M, Myint AM. The metabolic syndrome in schizophrenia: is inflammation a contributing cause? J Psychopharmacol. 2012;26:33–41.
24. Cakici N, van Beveren WUM, Judge-Hundal G, Koola MM, Sommer EC. An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis. Psychol Med. 2019;49:2307–19.
25. Tuominen HJ, Tihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2005;72:225–34.
26. Fan X, Goff DC, Henderson DC. Inflammation and schizophrenia. Expert Rev Neurother. 2007;7:789–96.
27. Song XQ, Lv LX, Li WQ, Hao YH, Zhao JP. The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia. Biol Psychiatry. 2009;65:481–8.
28. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2013;73:95–100.
29. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve–an integrative view. J Neuroimmune Pharmacol. 2012;7:656–64.
30. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2013;73:95–100.
31. Schwieler L, Larsson MK, Skogh E, Kegel ME, Orhan F, Abdelmoaty S, et al. Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia significance for activation of the kynurenic pathway. J Psychiatry Neurosci. 2015;40:126–33.
32. Schwieler L, Erhardt S, Erhardt C, Engelb P. Prostaglandin-mediated control of rat brain kynurenine acid synthesis opposite actions by COX-1 and COX-2 isoforms. J Neural Transm. 2005;112:863–72.
33. Song X, Fan X, Li X, Zhang W, Gao J, Zhao J, et al. Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naive, first-episode schizophrenia. Psychopharmacology. 2014;231:319–25.
34. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve–an integrative view. J Neuroimmune Pharmacol. 2012;7:656–64.
35. Leonard BE, Schwartz M, Myint AM. The metabolic syndrome in schizophrenia: is inflammation a contributing cause? J Psychopharmacol. 2012;26:33–41.
AUTHOR CONTRIBUTIONS
All authors contributed to and have approved the final manuscript. Authors YZ and GY were involved in collecting the clinical information. Authors YFY, WQL, MS, and MLS contributed to the writing of the paper. Authors XS and LXL supervised the study.

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41398-021-01688-x.

Correspondence and requests for materials should be addressed to Xi Su or Luxian Lv.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021